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Background: Contemporary data on the immunologic, haematologic and virologic responses and predictors of
virologic failure after initiation of free antiretroviral treatment in Cameroon are needed to evaluate the current
treatment-monitoring algorithm and to complement efforts to scale-up and improve on the management of HIV
infections.
Methods: This was a cross-sectional study conducted between October 2010 and June 2012. A total of 951
participants aged 18–74 years were recruited from selected approved HIV treatment centres of the Northwest
and Southwest regions. This comprised 247 males and 704 females. Demographic, self-reported risk behaviours
and socioeconomic data were obtained using a structured questionnaire. Full blood and CD4 + T-cell counts
were done using standard automated techniques. Determination of viral load (VL) was done using Abbott
RealTime HIV-1m2000™ system. Data was analysed using SPSS version 17. The statistical significance level was
P < 0.05.
Results: The median duration of antiretroviral therapy (ART) was 24 months. The population mean CD4 + T-cell
count was 255.3 cells/μL [95% CI, 236.8 – 273.9]. Overall, 45.9%, 43.8% and 10.2% of the participants had CD4 + T-cell
counts of < 200 cells/μL, 200–499 cells/μL and > 500 cells/μL respectively. Anaemia was present in 26.2% of the
participants with 62.3%, 25.7% and 12% described as mild, moderate and severe anaemia respectively. Virologic failure
occurred in 23.2% of the participants with 12.3% having VL > 10,000 RNA copies/mL. Meanwhile 76.8% of patients
attained adequate viral suppression with 40.8% having undetectable viral load. The age group 18–29 years (p = 0.024),
co-infection with tuberculosis (p = 0.014), anaemia (p = 0.028) and distance from the treatment centre (p = 0.011)
independently predicted virologic failure.
Conclusion: The majority of the participants achieved adequate viral suppression after≥ 6 months of ART. Despite
these favourable immuno-haematologic and virologic outcomes, the National AIDS Control Program should step-up
efforts to improve on antiretroviral drug distribution, as well as proper assessment and management of anaemia, foster
early diagnosis and treatment of tuberculosis and enhance treatment adherence counselling especially in younger
patients.
Keywords: Immuno-haematologic, Predictors, Virologic failure, Antiretroviral therapy* Correspondence: wifon@yahoo.com
1Department of Microbiology and Parasitology, University of Buea, P.O. Box
63, Buea, Cameroon
4Faculty of Science Clinical Diagnostic Laboratory, University of Buea, Buea,
Cameroon
Full list of author information is available at the end of the article
© 2014 Meriki et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the ortd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Meriki et al. Infectious Diseases of Poverty 2014, 3:5 Page 2 of 11
http://www.idpjournal.com/content/3/1/5Multilingual abstracts
Please see Additional file 1 for translations of the abstract
into the six official working languages of the United Nations.
Background
The introduction of free antiretroviral therapy (ART)
has substantially improved on the health status of HIV
infected patients. Although high levels of adherence have
been reported in small-scale HIV programs in Sub-Saharan
Africa [1], more challenges arise as these programs scale-up
particularly in countries with a growing burden of HIV and
tuberculosis (TB), and limited healthcare management fa-
cilities [2]. Rapid scale-up of antiretroviral therapy is ac-
companied by an increasing risk of ART failure resulting
from HIV drug resistance and this is a major obstacle to
successful ART in HIV-infected patients [3]. ART failure
may result in progression to AIDS characterized by im-
munological and haematological complications and op-
portunistic infections [4] with increased risk of morbidity
and mortality.
Generally, clinical response to ART in resource-limited
settings is monitored with CD4 + T cell counts and some
hematologic indices [2,5]. For successful outcomes and
the amelioration of ARV treatment, the challenge is the
effective delivery of ART with the aim of attaining high
treatment success rates [5]. However, the assessment of
viraemia, which gives a glaring picture of disease progres-
sion as well as response to ART [6], is not part of this clin-
ical monitoring in our setting due to its unavailability and
cost [2]. With appropriate adherence to ART, it is ex-
pected that viral load drops to undetectable levels after ≥ 6
months of ART [7], which greatly reduces the likelihood
of sexual transmission [8], morbidity and mortality among
HIV infected patients. Therefore, identifying risk factors
predicting treatment outcomes would be a reliable alter-
native for achieving a high treatment success rate. These
identified risk factors could be useful for rendering effect-
ive support and services to patients at risk of treatment
failure before or during treatment.
HIV prevalence among adults between the ages of 15
and 49 years in Cameroon is 4.3% [9]. The Northwest
(NW) and the Southwest (SW) regions with over 1.8
million and 1.3 million inhabitants respectively [10]
shoulder the highest burden of HIV in the country with
prevalence of 6.3% and 5.7% respectively [9]. The preva-
lence of HIV in the NW region has been steadily high,
even though it declined from 8.5% recorded in 2010
[11]. The NW and SW regions have 16 and 15 approved
treatment centres respectively that take care of over 16,000
and 12,000 patients on ART respectively [11]. Therefore,
contemporary data on immunologic, haematologic and vi-
rologic responses after the initiation of free antiretroviral
therapy in Cameroon are needed to inform and comple-
ment efforts to scale-up and improve on the managementof HIV infection. In this study, we assess the immuno-
haematologic and virologic status as well as factors associ-
ated with virologic failure of HIV-1 infected patients on
ART in NW and SW regions of Cameroon.
Methods
This was a cross-sectional, hospital-based study involv-
ing HIV-infected patients enrolled on high active anti-
retroviral therapy (HAART), treated between October
2010 and June 2012. Participants were consecutively re-
cruited from the approved HIV treatment Centres of Buea
and Limbe Regional hospitals, the management units of
the Tiko Central Clinic and Kumba District hospital of
the Southwest region; the HIV treatment centre of the
Bamenda Regional hospital and the management unit of
St. Theresa Catholic Medical Centre of the Northwest re-
gion. A nurse assigned to the study obtained demographic
and self-reported risk behaviour and socioeconomic data
with a standardized questionnaire [12] after obtaining par-
ticipant’s consent.
Two blood samples (2 × 5 mL) were collected in ethyl-
ene diamine tetra-acetate vaccutainer tubes by a techni-
cian from each participant. One tube was centrifuged
(at 1100 g for 20 minutes) and plasma aliquoted and
stored at −20°C until needed. The second sample was
used for full blood count analysis using the auto haematol-
ogy analyser (BC-2800, Mindray Bio-Medical Electronics,
Shenzhen, China) and CD4 +T-cell count (BD Biosciences
FACSCount™, New Jersey, USA) following manufacturers’
instructions. Anaemia was defined as haemoglobin con-
centration < 11 g/dL [13]. Anaemia was further categorised
as mild (9.6 – 10.9 g/dL), moderate (8 – 9.5 g/dL) and se-
vere (< 8 g/dL). Plasma viral load (VL) was determined
using the Abbott RealTime HIV-1 m2000™ System (Abbott
Molecular Inc. Des Plaines, Illinois, USA) according to the
manufacturer’s instructions. Virologic failure was defined
as VL > 400 RNA copies/mL after ≥ 6 months of ART while
adequate suppression was VL ≤ 400 RNA copies/mL after ≥
6 months of ART [14].
The data was analysed with SPSS 17.0 (Statistical Package
for the Social Sciences, Chicago, Illinois). Continuous vari-
ables were compared using the t-test. Univariate analysis
was performed with Chi-square and only significant asso-
ciated risk factors were included in a logistic regression
model. Odds ratios (ORs) and nominal 95% confidence in-
tervals (CIs) were presented. A two-sided p-value < 0.05
was considered significant for all analyses. Ethical clear-
ance for the study was obtained from Cameroon National
Ethics Committee.
Results
Description of the study population
Of the 951 participants recruited for the study, 247 were
males [mean age: 42.9 years, 95% CI 41.6 – 44.1] and
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38.9]. Of 951 these participants, 163 were from the NW
and 788 from the SW regions. Over 50% of the study
participants were between the ages of 30 and 45 years
old. The majority (83.6%) of the study participants had a
monthly income of ≤ 50,000 XAF (~ ≤ 100 US dollars),
48.9% had attained more than 7 years of education,
while 41.7% reported to be currently married.
Most of the participants (88.3%) were receiving treat-
ment at approved treatment centres while 11.7% were
treated at the approved management units. The median
duration of ART was 24 months [Range: 1–156 months].
Most of the participants (72.9%) were on nevirapine
(NVP)-based regimen (17.5% on AZT/3TC/NVP and
55.4% on d4T/3TC/NVP) while 27.1% were on efavirenz
(EFV)-based regimen (12.6% on AZT/3TC/EFV, and
14.5% on d4T/3TC/EFV). The prevalence of smoking
and alcohol consumption in the study population was
9.1% and 54.3% respectively. Of the alcohol consumers,
48.2% were hazardous drinkers (male > 3 bottles of beer/
occasion and females > 2 bottles of beer/occasion), while
16% of the participants both smoked and drank alcohol.
Smoking (p < 0.001) and alcohol consumption (p = 0.003)
were significantly higher among males than female partici-
pants. A total 10.8% of the study participants were co-
infected with tuberculosis (Table 1).
Immunologic responses
CD4+T-cell count measurements were performed in 479
of the 951 participants. The population mean CD4-T-cell
count was 255.3 cells/μL [95% CI, 236.8 – 273.9]. Mean
CD4-T-cell count was significantly higher (p < 0.001) in
participants from the SW than NW regions and in the
age group > 45 years when compared with those younger
(p = 0.018) (Table 2). This was also true for HIV mono-
infected (p < 0.001) when compared with HIV/TB co-infected
patients. However, there was no significant difference
(p = 0.171) in the mean CD4 + T-cell count in patients
who were treated with Efavirenz-based and Nevirapine-
based regimens. Similarly, CD4 + T-cell count was not sig-
nificantly different (p = 0.397) between males and females
(Table 3). Overall, 45.9%, 43.8% and 10.2% of the partici-
pants had CD4 + T-cell counts of < 200 cells/μL, 200–499
cells/μL and > 500 cells/μL respectively. CD4 + T-cell
counts of < 200 cells/μL were significantly higher in HIV/
TB co-infected cases (p < 0.001) and in patients from the
NW region (p = 0.002) (Figure 1).
Haematologic responses
A significant difference in haematological parameters for
participants from the two regions was observed only in
red blood cell (RBC) counts (p < 0.001). Gender had a sig-
nificant influence (p < 0.02) on mean haemoglobin (Hgb),
RBC and platelet (PLT) counts except white blood cell(WBC) count (Table 2). HIV-mono infected patients
had a significantly higher level of WBC (p = 0.004), PLT
(p = 0.035), RBC counts and Hgb (p < 0.001) when com-
pared with HIV/TB co-infected counterparts. On the
other hand, there was no significant difference in most
haematologic parameters between EFV-based and NVP-
based regimens except for an increase in platelet count
levels which was significantly higher (p = 0.024) among
patients on EFV-based regimen (Table 3). In general,
the prevalence of anaemia (Hgb < 11 g/dl), neutro-
penia (WBC < 2000 cells/mm3) and thrombocytopenia
(PLT < 125 × 103 cells/mm3) in the study participants
was 26.2%, 1.6% and 5.9% respectively. Among anaemic
patients, 62.3%, 25.7% and 12% had mild, moderate and
severe anaemia respectively. Anaemia was significantly
higher in patients from the NW region (p = 0.003) when
compared to those from SW region. Similarly, females
(p < 0.001) and HIV/TB co-infected patients (p < 0.001)
were more anaemic when compared to males and
HIV-mono-infected patients respectively (Figure 2). There
was no significant difference (p = 0.959) in the preva-
lence of anaemia between patients on AZT-containing
regimen (24.9%) compared with those not on AZT regimen
(25.1%).
Virologic responses
Of the 951 participants, viral load was performed in 89.3%
(849/951) and detected in 59.2%, while 40.8% of the partici-
pants had undetectable viral loads (< 40 RNA copies/mL)
at median treatment duration of 24 months (Range:
1–156 months). The difference in mean viral load was
insignificant (P > 0.05) between participants from the NW
and SW regions (Table 2), HIV mono-infected and HIV/
TB co-infected patients and in patients on EFV-based and
NVP-based regimens (Table 3). However, the mean viral
load was significantly different in the various age groups
(p = 0.033) with the highest mean load in those 18–29 years
of age (Table 2). The prevalence of virologic failure was
23.2% at median treatment duration of 16 months
(Range: 6 – 132 months), while 76.8% attained adequate
viral suppression at median treatment duration of 28.5
months (Range: 6 – 156 months). Definite virologic failure
(> 10,000 RNA copies/mL) was 12.3% at median treatment
duration of 16 months (Range: 6–132 months). Definite
virologic failure was significantly prominent in the age
group 18–29 years (18.5%, p = 0.013), in HIV/TB co-
infected patients (24.5%, p < 0.001) and among participants
from the NW region (20%, p = 0.013) (Figure 3).
Haemoglobin concentration (r = 0.208, p < 0.001), RBC
(r = 0.129, p = 0.009) and WBC (r = 0.168, p = 0.001)
counts correlated significantly with CD4 + T-cell counts.
Both haematologic and CD4 + T-cell counts showed a
negative correlation with viral load although not statisti-
cally significant (p > 0.05). Generally, mean Hgb and
Table 1 Baseline characteristics of study participants
categorized by gender
Variables Category Overall Male Female P-value
n (%) n (%) n (%)
Socio-demographic
Age group (year):
18 – 29 153 (16.1) 19 (12.4) 134 (87.6) < 0.001
30 – 45 561 (59.0) 144 (25.7) 417 (74.3)
> 45 237 (24.9) 84 (35.4) 153 (64.6)
Marital status:
Currently 303 (41.7) 133 (43.9) 170 (56.1) < 0.001
Never 231 (31.8) 37 (16.0) 194 (84.0)
Previously 193 (26.5) 18 (9.3) 175 (90.7)
Income level (XAF):
≤ 50,000* 628 (83.6) 143 (22.8) 485 (77.2) < 0.001
> 50,000 123 (16.4) 50 (40.7) 73 (59.3)
Level of education:
≤ 7years of school (low) 368 (48.9) 93 (25.3) 275 (74.7) 0.747
> 7 years of school (high) 384 (51.1) 101 (26.3) 283 (73.7)
Region of residence:
South West 788 (82.9) 198 (25.1) 590 (74.9) 0.191
North West 163 (17.1) 49 (30.1) 144 (69.9)
Management Facility:
AMU 111 (11.7) 33 (29.7) 78 (70.3) 0.337
ATC 840 (88.3) 214 (25.5) 626 (74.5)
Behavioural
Smoking:
Yes 71 (9.1) 48 (67.6) 23 (32.4) < 0.001
No 708 (90.9) 151 (21.3) 557 (78.7)
Alcohol use:
Yes 423 (54.3) 126 (29.8) 297 (70.2) 0.003
No 356 (45.7) 73 (20.5) 283 (79.5)
Hazardous alcohol useф 204 (48.2) 61 (29.9) 143 (70.1) 0.960
Standard alcohol use 219 (51.8) 65 (29.7) 154 (70.3)
Alcoholic-smoker:
Both 68 (16.0) 46 (67.6) 22 (32.4) < 0.001
Drinks or smokes 358 (84.0) 82 (22.9) 276 (77.1)
Clinical history
TB co-infection:
Yes 90 (10.8) 27 (30.0) 63 (70.0) 0.354
No 746 (89.2) 190 (25.5) 556 (74.5)
Regimen base:
NVP 614 (72.4) 145 (23.6) 469 (76.4) 0.044
EFV 234 (27.6) 71 (30.3) 163 (69.7)
Table 1 Baseline characteristics of study participants
categorized by gender (Continued)
Duration of ART:
< 12 months 216 (25.2) 57 (26.4) 159 (73.6) 0.888
12 – 36 months 390 (45.6) 103 (26.4) 287 (73.6)
> 36 months 250 (29.2) 62 (24.8) 288 (75.2)
SD-standard deviation, XAF- Central African CFA franc, *50,000 XAF=~ 100 US dollars,
AMU-approved management unit, ATC-Approved treatment centre, ф Hazardous
alcohol use (Female < 3 and male < 4 bottles of beer/occasion), EFV-Efavirenz,
NVP-Nevirapine.
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Factors associated with virologic failure
In a univariate analysis, socio-demographic (Table 4) and
behavioural variables (Table 5) except age did not have any
significant influence on the prevalence of virologic failure.
Failure was associated with the age groups 18–28 years
(OR 2.81, 95% CI: 1.55 – 5.10) and 30–45 years (OR 1.95,
95% CI: 1.21 – 3.13). Similarly, patients from the NW
region had a higher odds (OR 1.79, 95% CI: 1.16 – 2.76) of
experiencing virologic failure than those from SW region.
Distance from treatment centres was also an important
determinant of virologic failure. Patients living out of the
municipality were more likely to experience virologic failure
(OR 2.30, 95% CI: 1.53 – 3.46) than their counterparts
residing within the municipality (Table 4).
Similarly, duration of ART, co-infection with TB,
CD4 + T-cell count and anaemic status were associated
with virologic failure. HIV/TB co-infected patients had
remarkably higher odds (OR 3.24, 95% CI: 1.80 – 5.84) of
experiencing virologic failure than HIV mono-infected
patients, while patients on ART for < 12 months had
higher odds (OR 4.24, 95% CI 2.49 – 7.23) than those who
have been on ART for 12–36 months and > 36 months.
Similarly, anaemic patients (OR 2.48, 95% CI: 1.52 – 4.07)
and patients with CD4+ T-cell count < 200 cells/μL
(OR 2.49, 95% CI: 1.0 – 6.31) were also prone to failing
ART. Nonetheless, there was no significant difference
in virologic failure between those on NVP-based and
EFV-based regimen (Table 5).
In a multivariate analysis, involving all significantly
associated variables except region of residence, the age
group 18–29 years (AOR 0.27, 95% CI: 0.10 – 0.83), co-
infection with TB (AOR 0.20, 95% CI: 0.04– 0.70) and
anaemic patients (AOR 2.30, 95% CI: 1.10 – 4.83) were
again associated with virologic failure. Another model
which included all significant variables except HIV/TB
co-infection, revealed that the age group 18 – 29 years
(p = 0.022), anaemia (p = 0.024) and distance from treat-
ment centre (p = 0.011) with the same adjusted odd ratios
as in the previous model were associated with virologic
failure.
Table 2 Mean CD4 + Tcell count, viral load and haematologic parameters of study participants, grouped by region, age
and gender
CD4+ T-cell count Log10 viral load Mean haematologic parameters ± SD
Variables Category N Mean ± SD
[cells/μL]











Northwest 59 174.9 ± 120.1 75 3.32 ± 1.38 99 11.69 ± 2.21 3.42 ± 0.61 4.24 ± 1.61 2.25 ± 1.05
Southwest 420 266.7 ± 213.8 273 3.13 ± 1.31 538 12.07 ± 2.00 3.69 ± 0.62 4.41 ± 1.63 2.36 ± 0.77
p-value 0.001 0.275 0.094 < 0.001 0.342 0.199
Age groups (years)
18-29 74 200.1 ± 154.8 75 3.35 ± 1.33♠ 87 11.42 ± 1.69† 3.62 ± 0.53 3.99 ± 1.31‡ 2.40 ± 0.88
30-45 278 256.8 ± 198.7ᶲ 195 3.23 ± 1.34♠ 371 12.09 ± 2.14 3.69 ± 0.66 4.44 ± 1.79 2.35 ± 0.78
> 45 127 285.8 ± 242.3ᶲ 78 2.84 ± 1.24 179 12.15 ± 1.94 3.58 ± 0.60 4.45 ± 1.36 2.32 ± 0.86
p-value 0.018 0.033 0.012 0.124 0.049 0.732
Gender
Male 125 241.9 ± 177.9 98 3.13 ± 1.37 158 13.24 ± 2.16 3.93 ± 0.72 4.39 ± 1.55 2.20 ± 0.76
Female 354 260.1 ± 215.9 250 3.19 ± 1.31 479 11.61 ± 1.83 3.56 ± 0.57 4.39 ± 1.65 2.39 ± 0.83
p-value 0.397 0.724 < 0.001 < 0.001 0.996 0.010
♠ Higher than 30–45 and > 45 years [p < 0.025], ᶲ higher than 18–29 years [p < 0.037], § higher than < 12 months [p = 0.03], * higher than < 12 months and
12–36 months [p < 0.001], †lower than 30–45 years and > 45 years [p < 0.005], ‡ lower than 30–45 and > 45 years [p < 0.03].
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Diminution of CD4 + T-cells and haematological compli-
cations are hallmarks of HIV disease progression [15] as-
sociated with increase morbidity and mortality [16]. The
incidence and severity of these factors generally correlate
with the stage of the disease with anaemia being the
most common and important haematologic predictor of
HIV progression to AIDS [17]. In combination withTable 3 Mean CD4 + Tcell count, viral load and haematologic p
regimen type and co-infection status
CD4+ T-cell count Log10 viral load
Variables Category N Mean ± SD
[cell/μL]
N Mean ± SD
[copies/mL]
ART duration (Months)
< 12 106 168.9 ± 143.8 118 3.60 ± 1.27
12 – 36 255 266.3 ± 214.1§ 153 3.07 ± 1.38
> 36 130 318.7 ± 220.5* 60 2.93 ± 1.05
p-value < 0.001 0.001
Regimen type
EFV-based 163 241.0 ± 186.4 84 3.20 ± 1.37
NVP-based 297 268.9 ± 219.8 243 3.26 ± 1.30
p-value 0.171 0.683
Co-Infection status
HIV only 398 274.3 ± 216.6 255 3.18 ± 1.35
HIV/TB 66 171.1 ± 112.1 42 3.50 ± 1.34
p-value < 0.001 0.166
EFV-Efavirenz, NVP-Nevirapine, § higher than < 12 months [p = 0.03], * higher than < 12
[p < 0.02], ⍑ lower than > 36 months [p = 0.02], ∞ higher than < 12 months [p = 0.012], δother clinical markers, immuno-haematologic parame-
ters are used routinely in the evaluation and monitoring
of HIV-infected persons especially in resource limited
settings. They are relatively reliable indicators of prog-
nosis that complement the viral load assay and there-
fore guide therapeutic decisions regarding antiretroviral
treatment [18]. On the other hand, peak viral levels in
adults are not predictive of the rate of disease progressionarameters of study participants grouped by ART duration,









135 11.54 ± 2.09ℓ 3.58 ± 0.61 4.10 ± 1.49 2.50 ± 0.95
294 11.97 ± 1.90₸ 3.63 ± 0.59 4.33 ± 1.61 2.29 ± 0.77
192 12.56 ± 2.06 3.78 ± 0.66∞ 4.69 ± 1.75δ 2.36 ± 0.77
< 0.001 0.008 0.004 0.054
179 11.91 ± 1.96 3.59 ± 0.59 4.28 ± 1.65 2.48 ± 0.97
436 12.12 ± 2.06 3.69 ± 0.63 4.44 ± 1.65 2.31 ± 0.75
0.241 0.087 0.287 0.024
574 12.14 ± 2.02 3.71 ± 0.62 4.44 ± 1.67 2.36 ± 0.76
63 10.89 ± 1.86 3.09 ± 0.42 3.89 ± 1.06 2.20 ± 1.22
< 0.001 < 0.001 0.011 0.154
months and 12–36 months [p < 0.001], ℓ lower than 12–36 and > 36 months









NW SW 18-29 30-45 > 45 Male Female EFV NVP HIV only HIV/TB







< 200 200 - 499 ≥ 500
CD4+-T-cell (cellsµL)
Figure 1 Prevalence of immunologic categories among study participants.
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measure of the dynamics between the virulence of the
virus strain and the ability of the host immune system to
contain the virus, is highly predictive of disease progres-
sion [19].
In the present study, there was generally, an overall im-
provement in the means of immunologic and hematologic
parameters of study participants with ART duration. The
means of all haematologic parameters except that for
platelet counts were significantly higher (p < 0.001) in pa-
tients who at recruitment were on ART for > 36 months.
This increase in immuno-hematologic parameters corre-
sponded with a significant decrease in mean viral loads
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Figure 2 Prevalence of anaemia [Hgb < 11 g/dl] among study participA rise in CD4 + T-cell counts significantly correlated
with increase values of Hgb (p < 0.001), RBC (p < 0.009)
and WBC (p = 0.001) and these constitute indicators of
improved treatment outcome. These findings corroborate
previous studies that demonstrated an improvement in
the haematological and immunological parameters as
well as reduced morbidity and mortality in HIV in-
fected persons who had been on HAART for a long dur-
ation [20,21].
There was also a demographic disparity in immuno-
haematologic parameters. Over 70% of participants in
the current study were females. Previous studies have
also reported a high female population as well as the fact
that females are infected early in life than males [22],Male Female EFV NVP HIV only HIV/TB
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Figure 3 Prevalence of virologic categories among study participants.
Table 4 Demographic and socio-economic factors associated with virologic failure and risk estimates
Factors Demographic Virologic responses: prevalence, n (%) Risk estimates (95% CI)
N VF AS p-value Crude odd ratio Adjusted odd ratio p-value
Gender:
Male 175 46 (26.3) 129 (73.7) 0.260 1.26 (0.84-1.87)
Female 502 111 (22.1) 391 (77.9) 1
Age (years):
18 – 29 96 31 (32.3) 65 (67.7) 0.002 2.81 (1.55-5.10) 0.27 (0.10-0.83) 0.024
30 – 45 402 100 (24.9) 302 (75.1) 1.95 (1.21-3.13) 0.44 (0.20-1.07) 0.079
> 45 179 26 (14.5) 153 (85.5) 1 1
Region:
Northwest 120 39 (32.5) 81 (67.5) 0.008 1.79 (1.16-2.76) 0.20 (0.10-0.74)*
Southwest 557 118 (21.2) 439 (78.8) 1 1
Distance to TC:
Out of municipality 281 80 (28.5) 201 (71.5) < 0.001 2.30 (1.53-3.46) 0.42 (0.20-0.94) 0.011
Within municipality 312 46 (14.7) 266 (85.3) 1 1
Socio-economic
Level of education
Low (≤ 7yrs. of school) 273 46 (16.8) 227 (83.2) 0.118 0.72 (0.47-1.09)
High (> 7 yrs. of school) 309 68 (22.0) 241 (78.0) 1
Income level:
≤ 50,000 XAF ɖ 480 94 (19.6) 386 (80.4) 0.960 0.99 (0.58-1.69)
> 50,000 XAF 101 20 (19.8) 81 (80.2) 1
Marital status:
Never married 167 45 (25.7) 124 (74.3) 1.57 (0.92-2.69)
Currently married 245 42 (17.1) 203 (82.9) 0.079 0.94 (0.55-1.59)
Previously married 155 28 (18.1) 127 (81.9) 1
* Model including region of residence and excluding HIV/TB co-infection, VF: Virologic failure (viral load > 400 RNA copies/mL after 6 months of ART), AD:
Adequate suppression (≤ 400 RNA copies/mL after 6 months of treatment), TC: treatment centre, CI- confidence interval, ɖ 50,000 XAF = ~ 100 US dollars.
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Table 5 Behavioural and clinical factors associated with virologic failure and risk estimates
Factors Behavioural Virologic responses: prevalence, n (%) Risk estimates (95% CI)
N VF AS p-value Crude odd ratio Adjusted odd ratio p-value
Alcohol:
Yes 313 65 (20.8) 248 (79.2) 0.927 0.98 (0.66-1.46)
No 280 59 (21.1) 221 (78.9) 1
Smoking:
Yes 55 15 (27.3) 40 (72.7) 0.223 1.48 (0.79-2.77)
No 538 109 (20.3) 429 (79.7) 1
Clinical history
Duration of ART
(months): ≤ 12 108 48 (44.4) 60 (55.6) < 0.001 4.24 (2.49-7.23) 1.11 (0.40-3.16) 0.851
12-36 361 76 (21.1) 285 (78.9) 1.41 (0.90-2.22) 1.57 (0.73-3.36) 0.251
> 36 208 33 (15.9) 175 (84.1) 1 1
Regimen type:
EFV-based 177 35 (19.8) 142 (80.2) 0.232 0.77 (0.51-1.18)
NVP-based 492 119 (24.2) 373 (75.8) 1
Co-infection status:
HIV/TB co-infected 51 22 (45.1) 28 (54.9) < 0.001 3.24 (1.80-5.84) 0.20 (0.04-0.70) 0.014
HIV only 589 119 (20.2) 470 (79.8) 1 1
CD4+T-cell (cells/μL):
< 200 154 46 (29.9) 108 (70.1) 0.002 2.49 (1.0-6.31) 0.68 (0.23-2.05) 0.497
200 - 499 165 24 (14.5) 141 (85.5) 1.69 (0.63-4.49) 1.22 (0.40-3.75) 0.724
≥ 500 41 06 (14.6) 35 (85.4) 1 1
Anaemic status (g/dL):
Anaemic 114 34 (29.8) 80 (70.2) < 0.001 2.48 (1.52-4.07) 2.30 (1.10-4.83) 0.028
Non-anaemic 376 55 (14.6) 321 (85.4) 1 1
VF: Virologic failure (viral load > 400 RNA copies/mL after ≥ 6 months of ART), AS: Adequate suppression (≥ 400 RNA copies/mL after ≥ 6 months of ART), Anaemia:
Hgb < 11 g/dl, CI - confidence interval.
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health-seeking attitude than males [24]. Our results
show that increase in age had a better prediction in
terms of immuno-haematologic and virologic responses
to ART. Furthermore, the mean CD4 + T-cell count of
HIV/TB co-infected patients was 1.6 times lower than
that of HIV mono-infected persons. Co-infected patients
were also more anaemic than HIV mono-infected pa-
tients, which is in line with a previous report by Kufa
et al. [25]. CD4 + T-cell-count of < 200 cells/μL was pre-
dominant among HIV/TB co-infected patients (Figure 1).
In a previous study, CD4 + T-cell count < 200 cells/μL
was associated with an increased risk of anaemia [26].
Mean viral load and CD4 + T-cell counts did not differ
between males and females, although prior studies
[27,28] suggest a significant influence of gender on viral
dynamics and the immune response. In a recent report,
women showed consistently better immune responses to
treatment than did men in a virally suppressed popula-
tion [29]. However, in our study, females were moreat risk of developing anaemia compared with males
(p < 0.001) which is in line with findings by Levine et al.
[30] who attributed this difference to sex and race. Similar
findings by Volberding et al. [31] attributed anaemia to
menstrual blood loss in women and to the drain on iron
stores that occur with pregnancy and delivery. Even with
the use of HAART, anaemia remains strongly and consist-
ently associated with HIV disease progression [32]. Al-
though the prevalence of severe anaemia has decreased
since the introduction of HAART, mild-to-moderate an-
aemia continues to be common [33]. In this study, 61.3%,
26.9% and 11.8% of anaemic patients suffered from mild,
moderate and severe anaemia respectively. Our study
did not show any significant difference in the occur-
rence of anaemia between patients on zidovudine-containing
regimens and those without as also reported by Semba
et al. [34].
In line with previous reports our results further indi-
cated that there was no significant difference in mean
CD4 count [35] and mean viral load [36,37] in those
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contrast to another report [38] that showed a better out-
come with Efavirenz-based ART compared with Nevira-
pine. The lower mean immuno-hematologic parameters
seen in participants from the NW when compared with
those from the SW region was probably because most
of the HIV/TB co-infected patients were from the NW
region. Moreover, our results showed HIV co-infection
with TB was associated with poor immunologic and
hematologic responses.
Attaining and maintaining viral load to an undetectable
level is the key to mitigating long-term risk of AIDS-
defining illnesses among HIV-positive patients with low
CD4 counts. Patients who are initiated on ART and experi-
ence rapid CD4 increase, have a lower risk of AIDS illness
than those with a slow response. Nonetheless, this difference
diminishes after six months provided that viral load remains
undetectable [39]. At a median treatment duration of 24
months, 40.8% of the study participants had undetectable
viral loads with an overall 76.8% adequate viral suppression
rate at a median treatment duration of 28.5 months. The
prevalence of virologic failure was 23.2% of which 12.3%
reflected a definite virologic failure. These rates are similar
to those reported in other resource-limited settings [40] and
comparable to those reported in developed countries. In
spite of earlier incertitude, this shows that ART programs
based on the public health approach using similar regimens
in resource-limited countries, perform as effective as those
seen in clinical cohorts in developed countries [41-43].
Even though socioeconomic status has been associated
with HIV treatment outcomes [44] our study surprisingly
did not suggest an association between socio-economic or
behavioural predictors of virologic failure. However, partici-
pants from the NW region, and patients residing far from
treatment centres were more likely to experience virologic
failure. Previous studies and extensive reviews on barriers to
accessing HIV treatment and negative treatment outcomes
suggest that longer distances from treatment sites are associ-
ated with poorer outcomes [45,46].
The higher occurrence of virologic failure in the younger
age group of 18–29 years corroborates a previous report by
Anude et al. [47] and this can be attributed mainly to non-
adherence to treatment among the youths [46]. Other
studies have also demonstrated that improved ART
outcomes increases with age [48]. Similarly, virologic
failure was common among HIV/TB co-infected and an-
aemic patients as well as in patients with CD4 + T-cell
counts of < 200 cell/μL. Studies conducted by Skowron
et al. [49] demonstrated that CD4 + T-cell count is
a better predictor of viral suppression. Likewise, Bello
et al. [50] showed that TB co-morbidity had a signifi-
cant influence on the occurrence of virologic failure by
accelerating the course of HIV induced disease resulting
from CD+T-cells decline.Conclusions
This study demonstrates a favourable immuno-haematologic
and virologic outcome following antiretroviral therapy.
Anaemia, co-infection with TB, the age group 18–29 years
and distance from the treatment centre independently pre-
dicted virologic failure. Despite this favourable outcome, it
is imperative for the National AIDS Control Committee
(NACC) to step-up efforts to improve on ARV distribu-
tion, proper assessment and management of anaemia, early
diagnosis and treatment of TB and treatment adherence
counselling especially in younger patients.
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